Kymera Expands KT-474 (SAR444656) HS and AD Phase 2 Studies

  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that following a review of preliminary KT-474 safety and efficacy data by an Independent Data Review Committee, Sanofi has informed Kymera that it intends to expand the ongoing Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD) Phase 2 trials to more rapidly progress towards pivotal studies.

https://www.globenewswire.com/news-release/2024/07/08/2909952/0/en/Kymera-Announces-Expansion-of-KT-474-SAR444656-HS-and-AD-Phase-2-Studies-Following-Interim-Review-of-Safety-and-Efficacy.html